HER2 Flip Flop: OncoTherapy Network & Cancer Network
(MedPage Today) -- Also, higher BMI linked to better metastatic RCC survival (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 28, 2016 Category: Hematology Source Type: news

Breast Cancer CTCs Can Flip Between HER2 Negativity and Positivity
Breast cancer tumors that are HER2-negative can spontaneously flip, with populations of circulating HER2-positive cells, suggesting treatment strategy. (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Puma Biotechnology Announces FDA Acceptance of NDA for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES, Calif., Sept. 20, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead product... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 20, 2016 Category: Drugs & Pharmacology Source Type: news

Updated FISH Guidelines Increase Eligible HER2-Positive Breast Cancer Patients
Using updated FISH guidelines yields more women with breast cancer who may be eligible for HER2-directed therapy. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

EMA accepts Mylan ’s MAA for proposed biosimilar trastuzumab for review
The European Medicines Agency (EMA) has accepted for review Mylan's marketing authorisation application (MAA) for a proposed biosimilar Trastuzumab, MYL-1401O, to treat certain human epidermal growth factor receptor 2 (HER2)-positive breast and gastr … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 25, 2016 Category: Pharmaceuticals Source Type: news

New standard helps ensure accurate clinical measurements of HER2 breast cancer gene
Study demonstrates value of new measurement reference for both evaluating assay performance and increasing confidence in reporting HER2 amplification for clinical applications. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 17, 2016 Category: Science Source Type: news

New standard helps ensure accurate clinical measurements of HER2 breast cancer gene
(National Institute of Standards and Technology (NIST)) Study demonstrates value of new measurement reference for both evaluating assay performance and increasing confidence in reporting HER2 amplification for clinical applications. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 17, 2016 Category: Biology Source Type: news

Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation as First-Line Treatment for HR+/HER2- Advanced Breast Cancer
EAST HANOVER, N.J., Aug. 3, 2016 -- (Healthcare Sales & Marketing Network) -- Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for t... Biopharmaceuticals, Oncology, FDA Novartis, ribociclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 3, 2016 Category: Pharmaceuticals Source Type: news

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. (Source: World Pharma News)
Source: World Pharma News - August 3, 2016 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Updated testing guidelines make more women eligible for herceptin, yet benefit uncertain
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study. Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2-positive and can be treated with drugs like Herceptin that target HER2. HER2 stands for human epidermal growth factor receptor 2. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 27, 2016 Category: Science Source Type: news

Updated testing guidelines make more women eligible for herceptin, yet benefit uncertain
( Mayo Clinic ) Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2-positive and can be treated with drugs like Herceptin that target HER2. HER2 stands for human epidermal growth factor receptor 2. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 27, 2016 Category: Cancer & Oncology Source Type: news

Updated Testing Guidelines Make More Women Eligible for Herceptin, yet Benefit Uncertain
ROCHESTER, Minn. — Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. Cancers that have an excess of HER2 protein or extra copies of th e HER2 gene are called [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - July 27, 2016 Category: Research Source Type: news

Puma reports interim Phase III ExteNET trial results of PB272 to treat HER2-positive breast cancer
US-based biopharmaceutical company Puma Biotechnology has reported interim 5-year disease free survival data from the Phase III ExteNET trial of PB272 (neratinib) for an adjuvant treatment of early stage, HER2-positive breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 26, 2016 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
THOUSAND OAKS, Calif. and DUBLIN, July 21, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. The results ruled out inferiority compared to trastuzumab but could not rule out superiority based on its primary efficacy endpoint of the difference of the percentage of patients with a pathologic complete response (pCR). The primary endpoint had a prespecified equivalence margin of +/- 13 perc...
Source: Amgen News Release - July 21, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES, Calif., July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 21, 2016 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim and Lilly announce clinical trial collaboration in metastatic breast cancer
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralising antibody, in combination with abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in patients diagnosed with HR+/HER2- mBC. (Source: World Pharma News)
Source: World Pharma News - July 13, 2016 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Emerging Therapies for Metastatic Breast CancerEmerging Therapies for Metastatic Breast Cancer
Therapeutic options are set to increase for patients with refractory HR-positive or HER2-positive metastatic breast cancer, as evidenced by presentations at ASCO 2016. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 22, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Can Anthracyclines Be Withheld in High-Risk HER2- Breast Cancer?Can Anthracyclines Be Withheld in High-Risk HER2- Breast Cancer?
At ASCO 2016, the results of the ABC suite of trials provided guidance on a very important clinical question in breast cancer management. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Cheaper Breast Cancer Drug Does Well in Clinical Trial
It has similar effectiveness, safety compared to Herceptin for HER2-positive disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 4, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Oncology, Pharmacy, Research, News, Source Type: news

Cheaper Breast Cancer Drug Shows Promise
It has similar effectiveness, safety compared to Herceptin for HER2-positive disease (Source: WebMD Health)
Source: WebMD Health - June 3, 2016 Category: Consumer Health News Source Type: news

Cheaper Breast Cancer Drug Does Well in Clinical Trial
FRIDAY, June 3, 2016 -- For women with advanced HER2-positive breast cancer, a similar but less expensive experimental drug works just as well as the standard drug Herceptin (trastuzumab), a new study finds. HER2-positive tumors contain certain... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2016 Category: Journals (General) Source Type: news

Promising treatment prospects for invasive breast cancer
In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms of breast cancer, the cells have too much of the receptor HER2 on their surface. This leads to uncontrolled growth of the cells. (Source: World Pharma News)
Source: World Pharma News - June 3, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Cheaper Breast Cancer Drug Does Well in Clinical Trial
It has similar effectiveness, safety compared to Herceptin for HER2-positive disease (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 3, 2016 Category: Cancer & Oncology Source Type: news

Breast Cancer: Big Questions Answered?Breast Cancer: Big Questions Answered?
Dr Kathy Miller previews the top ASCO 2016 breast cancer studies, which may provide definitive answers about anthracyclines in HER2-negative BC and optimal duration for adjuvant aromatase inhibitors. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

HER2+ Colorectal Cancer: Slicing the Pie Into Curable PortionsHER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions
Dr John Marshall views a study of dual targeting in HER2+ CRC as an argument for combining broad molecular testing and precision medicine to slice the cancer pie into curable portions. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2016 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

HER2 Therapy in Advanced Colorectal Cancer: 'Extraordinary'HER2 Therapy in Advanced Colorectal Cancer: 'Extraordinary'
Treatment-refractory HER2-positive metastatic colorectal cancer patients achieve remarkable response to a combination targeted therapy regimen. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 3, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Neoadjuvant Combination for HER+ Breast CancerNew Neoadjuvant Combination for HER+ Breast Cancer
A presurgery combination of trastuzumab emtansine and pertuzumab was significantly better than the standard of care, paclitaxel and trastuzumab, for HER2+ invasive breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

'Disturbing' Disparity in Use of Key Breast Cancer Drug'Disturbing' Disparity in Use of Key Breast Cancer Drug
A study indicates that black patients with HER2+ breast cancer are 25% less likely to receive trastuzumab than are white patients--an underuse that may affect outcomes, reports Dr Lidia Schapira. Medscape Oncology (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 25, 2016 Category: Internal Medicine Tags: Hematology-Oncology Viewpoint Source Type: news

New ASCO Guide for Adjuvant Therapy in Early Breast CancerNew ASCO Guide for Adjuvant Therapy in Early Breast Cancer
ASCO has issued its first comprehensive clinical guidelines on adjuvant chemotherapy in early breast cancer and targeted adjuvant therapy for HER2-positive disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

High Marks for Novel Neoadjuvant Regimen (CME/CE)
(MedPage Today) -- T-DM1/pertuzumab tops standard therapy in HER2-positive breast cancer (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 20, 2016 Category: Hematology Source Type: news

Roche reports solid sales growth in the first quarter of 2016
In the first quarter of 2016, Group sales rose 4% to CHF 12.4 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 9.8 billion with Europe growing 5%, driven by Perjeta, MabThera and RoActemra. Pharmaceuticals sales in the US increased 3%, led by Esbriet, Xolair and HER2-positive breast cancer medicines. The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer have had a good start. (Source: World Pharma News)
Source: World Pharma News - April 19, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Is Breast Cancer Research Geared to Our Patients?Is Breast Cancer Research Geared to Our Patients?
Dr Piccart-Gebhart reviews the progress made in HER2-positive breast cancer and asks whether the 'fragmented' efforts of research answer--or even address--the questions most important to patients. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 18, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Penn Medicine presents evidence showing new drug combination may improve outcomes for women with advanced breast cancer when administered before surgery
(University of Pennsylvania School of Medicine) Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. Previous studies have shown that a combination of T-DM1 and pertuzumab is safe and effective against advanced, metastatic HER2-positive breast cancer, but in the new results, investigators tested whether the combination would also be effective if given earlier in the course of treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 18, 2016 Category: Global & Universal Source Type: news

Many older black women miss out on targeted breast cancer drug
(Reuters Health) - Older black women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer are less likely than their white peers to receive targeted therapy with trastuzumab (Herceptin), a U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Older women, especially blacks, receive targeted breast cancer treatment at low rates
(University of North Carolina at Chapel Hill) The advent of targeted drugs for a specific type of breast cancer -- HER2 positive -- has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2016 Category: Cancer & Oncology Source Type: news

Peptide-Based Cancer Vaccine Strategies and Clinical Results
Active cancer immunotherapy is an exciting and developing field in oncology research. Peptide vaccines, the use of isolated immunogenic tumor-associated antigen (TAA) epitopes to generate an anticancer immune response, are an attractive option as they are easily produced and administered with minimal toxicity. Multiple TAA-derived peptides have been identified and evaluated with various vaccine strategies currently in clinical testing. Research suggests that utilizing vaccines in patients with minimal-residual disease may be a more effective strategy compared to targeting patients with widely metastatic disease as it avoid...
Source: Springer protocols feed by Immunology - April 9, 2016 Category: Allergy & Immunology Source Type: news

Adjuvant endocrine therapy for premenopausal breast cancer patients should be individualized
Oncologists should take an individualized approach when making decisions about adjuvant endocrine therapies for premenopausal hormone receptor–positive, HER2-negative early breast cancer, suggests an... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 4, 2016 Category: Endocrinology Source Type: news

The tradeoffs: Personalized treatment vs. one-size-fits-all standards
What would happen if instead of a personalized treatment plan your doctor used a one-size-fits-all standard of care? A recent government proposal to change Medicare Part B could create barriers to personalized care. This case study looks at personalized treatment vs. one-size-fits-all standards. For a patient like Joyce, diagnosed with stage IV metastatic breast cancer, HER2 negative and managing other health conditions, the specific course of treatment has real implications. (Source: The Catalyst)
Source: The Catalyst - April 1, 2016 Category: Pharmaceuticals Tags: Medicare Payment and Delivery Reform Part B case studies Source Type: news

Preclinical Efficacy of T-DM1 in the Brain MicroenvironmentPreclinical Efficacy of T-DM1 in the Brain Microenvironment
Can T-DM1 overcome resistance to trastuzumab in treatment of brain metastases associated with HER2 positive breast cancer? Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 1, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

‘Modest support’ for PFS as OS surrogate in HER2-positive metastatic breast cancer
Progression-free survival only moderately correlates with overall survival at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with HER2-targeted agents, say researchers. (Source: MedWire News)
Source: MedWire News - March 23, 2016 Category: Consumer Health News Tags: Breast cancer Source Type: news

PFS No Surrogate for OS in Metastatic Breast Cancer TrialsPFS No Surrogate for OS in Metastatic Breast Cancer Trials
A meta-analysis looked at whether progression-free survival can serve as a surrogate endpoint for overall survival in metastatic HER2+ breast cancer -- and the answer is no, reports Dr Lidia Schapira. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 18, 2016 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Preoperative lapatinib plus trastuzumab elicits response in HER2-positive breast cancer
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research. (Source: MedWire News)
Source: MedWire News - March 15, 2016 Category: Consumer Health News Tags: Breast cancer Source Type: news

New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows
(Dana-Farber Cancer Institute) A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer Institute has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 14, 2016 Category: Cancer & Oncology Source Type: news

New Agent Overcomes Drug Resistance in HER2-Positive Breast Cancer, Preclinical Study Shows (Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center)
A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer Institute has found. The results, reported in Cancer Cell, prompted investigators to launch a clinical trial of the new agent in women with a metastatic form of this cancer, known as HER2-positive breast cancer. Dana-Farber/Brigham and Women's Cancer Center | Massachusetts Ge... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 14, 2016 Category: Cancer & Oncology Source Type: news

Medical News Today: Cancer breakthrough? Drug combo eradicated breast cancer tumors in 11 days
A cancer drug duo eliminated tumors for some women with HER2-positive breast cancer in only 11 days, while others saw a significant reduction in tumor size, new research reveals. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2016 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Herceptin plus tykerb makes breast cancer tumours 'disappear'
Results of a clinical trial of patients with HER2-positive breast cancer were presented at the European Breast Cancer Conference in Amsterdam. Patients treated with a combination of herceptin plus lapatinib showed significantly decreased tumour mass. The Independent (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 11, 2016 Category: Endocrinology Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - March 11, 2016 Category: Cancer & Oncology Source Type: news

Drug combo shrinks HER2 breast cancers 'within 11 days'
A drug combination taken before surgery shrinks and may even destroy tumours in women with HER2 positive disease within 11 days, a UK trial has found. (Source: Nursing Times)
Source: Nursing Times - March 11, 2016 Category: Nursing Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: WebMD Health)
Source: WebMD Health - March 10, 2016 Category: Consumer Health News Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 10, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news